Compare Stocks: DXR, OBIO, CNXU, and FOCL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNXU Conexeu Sciences	$8.31 -5.9%	$11.41	$7.10 ▼ $18.79	$222.36M	N/A	105,176 shs	164,804 shs
DXR Daxor	$10.67 +1.3%	$10.37	$8.56 ▼ $14.76	$62.26M	0.26	7,381 shs	870 shs
FOCL FocalTherics	$6.12 -0.3%	$5.22	$1.21 ▼ $6.36	$229.39M	-0.04	53,263 shs	36,847 shs
OBIO Orchestra BioMed	$3.98 -0.3%	$3.95	$2.20 ▼ $5.42	$238.33M	0.49	256,774 shs	153,853 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNXU Conexeu Sciences	+11.91%	-3.50%	-19.14%	+882,999,900.00%	+882,999,900.00%
DXR Daxor	+1.01%	+1.77%	+5.00%	-2.47%	+7.43%
FOCL FocalTherics	-1.76%	+0.82%	+18.53%	+613,999,900.00%	+613,999,900.00%
OBIO Orchestra BioMed	+5.00%	+9.62%	-7.64%	0.00%	+27.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNXU Conexeu Sciences	$8.31 -5.9%	$11.41	$7.10 ▼ $18.79	$222.36M	N/A	105,176 shs	164,804 shs
DXR Daxor	$10.67 +1.3%	$10.37	$8.56 ▼ $14.76	$62.26M	0.26	7,381 shs	870 shs
FOCL FocalTherics	$6.12 -0.3%	$5.22	$1.21 ▼ $6.36	$229.39M	-0.04	53,263 shs	36,847 shs
OBIO Orchestra BioMed	$3.98 -0.3%	$3.95	$2.20 ▼ $5.42	$238.33M	0.49	256,774 shs	153,853 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNXU Conexeu Sciences	+11.91%	-3.50%	-19.14%	+882,999,900.00%	+882,999,900.00%
DXR Daxor	+1.01%	+1.77%	+5.00%	-2.47%	+7.43%
FOCL FocalTherics	-1.76%	+0.82%	+18.53%	+613,999,900.00%	+613,999,900.00%
OBIO Orchestra BioMed	+5.00%	+9.62%	-7.64%	0.00%	+27.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNXU Conexeu Sciences	2.50	Moderate Buy	$20.00	140.67% Upside
DXR Daxor	2.50	Moderate Buy	N/A	N/A
FOCL FocalTherics	2.50	Moderate Buy	$9.00	47.06% Upside
OBIO Orchestra BioMed	2.57	Moderate Buy	$13.60	241.71% Upside

Current Analyst Ratings Breakdown

Latest DXR, OBIO, CNXU, and FOCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	OBIO Orchestra BioMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	FOCL FocalTherics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$15.00
7/17/2026	FOCL FocalTherics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/29/2026	CNXU Conexeu Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	DXR Daxor	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
6/22/2026	CNXU Conexeu Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/2/2026	FOCL FocalTherics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
5/19/2026	OBIO Orchestra BioMed	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00
5/14/2026	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
5/13/2026	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$12.00 ➝ $13.00

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A	N/A
DXR Daxor	$10.30M	6.04	N/A	N/A	N/A	∞
FOCL FocalTherics	$74.07M	3.10	N/A	N/A	$0.52 per share	11.77
OBIO Orchestra BioMed	$32.72M	7.28	N/A	N/A	$0.95 per share	4.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNXU Conexeu Sciences	N/A	-$0.11	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/20/2026 (Estimated)
FOCL FocalTherics	-$29.25M	-$0.81	N/A	N/A	N/A	-41.47%	-137.61%	-40.62%	8/27/2026 (Estimated)
OBIO Orchestra BioMed	-$52.70M	-$0.97	N/A	N/A	N/A	-166.96%	-157.46%	-60.18%	8/11/2026 (Estimated)

Latest DXR, OBIO, CNXU, and FOCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q2 2026	DXR Daxor	-$0.03	N/A	N/A	N/A	$2.80 million	N/A
8/27/2026	Q2 2026	FOCL FocalTherics	-$0.2287	N/A	N/A	N/A	$22.48 million	N/A
8/11/2026	Q2 2026	OBIO Orchestra BioMed	-$0.35	N/A	N/A	N/A	$0.14 million	N/A
6/15/2026	Q2 2026	CNXU Conexeu Sciences	N/A	-$0.11	N/A	-$0.11	N/A	N/A
5/12/2026	Q1 2026	OBIO Orchestra BioMed	-$0.40	-$0.33	+$0.07	-$0.33	$0.92 million	$0.11 million
5/7/2026	Q1 2026	FOCL FocalTherics	-$0.22	-$0.24	-$0.02	-$0.24	$19.46 million	$20.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
DXR Daxor	$0.03	0.28%	N/A	N/A	N/A
FOCL FocalTherics	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNXU Conexeu Sciences	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A
FOCL FocalTherics	1.79	1.34	0.99
OBIO Orchestra BioMed	0.35	7.03	7.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNXU Conexeu Sciences	N/A
DXR Daxor	1.34%
FOCL FocalTherics	62.74%
OBIO Orchestra BioMed	53.20%

Insider Ownership

Company	Insider Ownership
CNXU Conexeu Sciences	N/A
DXR Daxor	51.50%
FOCL FocalTherics	10.10%
OBIO Orchestra BioMed	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNXU Conexeu Sciences	4	26.76 million	N/A	N/A
DXR Daxor	37	5.84 million	2.83 million	Not Optionable
FOCL FocalTherics	230	37.48 million	33.70 million	N/A
OBIO Orchestra BioMed	4	59.88 million	55.39 million	Not Optionable

DXR, OBIO, CNXU, and FOCL Headlines

Recent News About These Companies

Orchestra BioMed Hldgs Stock Dividends | NASDAQ:OBIO | Benzinga

July 29 at 1:09 PM | benzinga.com

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Average Recommendation of "Moderate Buy" from Analysts

July 22, 2026 | americanbankingnews.com

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 22, 2026 | marketbeat.com

Biorestorative Therapies (NASDAQ:BRTX) vs. Orchestra BioMed (NASDAQ:OBIO) Financial Analysis

July 20, 2026 | americanbankingnews.com

Short Interest in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Grows By 79.5%

July 17, 2026 | marketbeat.com

Orchestra BioMed Holdings, Inc.

July 11, 2026 | cnn.com

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes

June 29, 2026 | globenewswire.com

Orchestra BioMed Shareholders Approve Directors and Incentive Plan

June 23, 2026 | tipranks.com

David Hochman Buys 5,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

June 3, 2026 | insidertrades.com

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

Insider Buying: Orchestra BioMed (NASDAQ:OBIO) Insider Purchases 5,000 Shares of Stock

May 20, 2026 | insidertrades.com

Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference

May 19, 2026 | globenewswire.com

Insider Buying: Orchestra BioMed (NASDAQ:OBIO) Director Purchases 20,000 Shares of Stock

May 19, 2026 | insidertrades.com

Orchestra BioMed Holdings (OBIO) Receives a Buy from H.C. Wainwright

May 16, 2026 | theglobeandmail.com

Orchestra BioMed Holdings (OBIO) price target increased by 11.30% to 12.68

May 15, 2026 | msn.com

Orchestra BioMed Holdings (OBIO) Gets a Buy from Piper Sandler

May 15, 2026 | theglobeandmail.com

Orchestra BioMed targets completed BACKBEAT enrollment by end of Q3 2026

May 13, 2026 | massdevice.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2026 | zacks.com

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

May 12, 2026 | globenewswire.com

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

May 12, 2026 | globenewswire.com

Orchestra Biomed picks up $35M from Medtronic, Ligand

May 7, 2026 | massdevice.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR, OBIO, CNXU, and FOCL Company Descriptions

Conexeu Sciences NASDAQ:CNXU

$8.31 -0.52 (-5.89%)

Closing price 04:00 PM Eastern

Extended Trading

$8.33 +0.02 (+0.19%)

As of 04:13 PM Eastern

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

Daxor NASDAQ:DXR

$10.66 +0.14 (+1.28%)

Closing price 03:57 PM Eastern

Extended Trading

$10.54 -0.13 (-1.17%)

As of 04:10 PM Eastern

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

FocalTherics NASDAQ:FOCL

$6.12 -0.02 (-0.33%)

As of 04:00 PM Eastern

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Orchestra BioMed NASDAQ:OBIO

$3.98 -0.01 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.98 0.00 (0.00%)

As of 04:10 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXR, OBIO, CNXU, and FOCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXR, OBIO, CNXU, and FOCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXR, OBIO, CNXU, and FOCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR, OBIO, CNXU, and FOCL Company Descriptions

Conexeu Sciences NASDAQ:CNXU

Daxor NASDAQ:DXR

FocalTherics NASDAQ:FOCL

Orchestra BioMed NASDAQ:OBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DXR, OBIO, CNXU, and FOCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DXR, OBIO, CNXU, and FOCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DXR, OBIO, CNXU, and FOCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR, OBIO, CNXU, and FOCL Company Descriptions

Conexeu Sciences NASDAQ:CNXU

Daxor NASDAQ:DXR

FocalTherics NASDAQ:FOCL

Orchestra BioMed NASDAQ:OBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools